AbbVie SG&A Expenses 2010-2024 | ABBV
AbbVie annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- AbbVie sg&a expenses for the quarter ending September 30, 2024 were $4.205B, a 24.7% increase year-over-year.
- AbbVie sg&a expenses for the twelve months ending September 30, 2024 were $14.090B, a 7.59% increase year-over-year.
- AbbVie annual sg&a expenses for 2023 were $12.872B, a 15.65% decline from 2022.
- AbbVie annual sg&a expenses for 2022 were $15.26B, a 23.57% increase from 2021.
- AbbVie annual sg&a expenses for 2021 were $12.349B, a 9.29% increase from 2020.
AbbVie Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$12,872 |
| 2022 |
$15,260 |
| 2021 |
$12,349 |
| 2020 |
$11,299 |
| 2019 |
$6,942 |
| 2018 |
$7,399 |
| 2017 |
$6,295 |
| 2016 |
$5,881 |
| 2015 |
$6,387 |
| 2014 |
$7,724 |
| 2013 |
$5,352 |
| 2012 |
$4,989 |
| 2011 |
$5,894 |
| 2010 |
$3,820 |
| 2009 |
$3,349 |
AbbVie Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$4,205 |
| 2024-06-30 |
$3,377 |
| 2024-03-31 |
$3,315 |
| 2023-12-31 |
$3,193 |
| 2023-09-30 |
$3,372 |
| 2023-06-30 |
$3,268 |
| 2023-03-31 |
$3,039 |
| 2022-12-31 |
$3,417 |
| 2022-09-30 |
$3,304 |
| 2022-06-30 |
$5,412 |
| 2022-03-31 |
$3,127 |
| 2021-12-31 |
$3,260 |
| 2021-09-30 |
$3,083 |
| 2021-06-30 |
$3,164 |
| 2021-03-31 |
$2,842 |
| 2020-12-31 |
$3,231 |
| 2020-09-30 |
$2,846 |
| 2020-06-30 |
$3,527 |
| 2020-03-31 |
$1,695 |
| 2019-12-31 |
$1,951 |
| 2019-09-30 |
$1,657 |
| 2019-06-30 |
$1,654 |
| 2019-03-31 |
$1,680 |
| 2018-12-31 |
$1,929 |
| 2018-09-30 |
$1,919 |
| 2018-06-30 |
$1,760 |
| 2018-03-31 |
$1,791 |
| 2017-12-31 |
$1,956 |
| 2017-09-30 |
$1,457 |
| 2017-06-30 |
$1,509 |
| 2017-03-31 |
$1,373 |
| 2016-12-31 |
$1,679 |
| 2016-09-30 |
$1,381 |
| 2016-06-30 |
$1,466 |
| 2016-03-31 |
$1,355 |
| 2015-12-31 |
$1,737 |
| 2015-09-30 |
$1,474 |
| 2015-06-30 |
$1,703 |
| 2015-03-31 |
$1,473 |
| 2014-12-31 |
$3,341 |
| 2014-09-30 |
$1,595 |
| 2014-06-30 |
$1,448 |
| 2014-03-31 |
$1,340 |
| 2013-12-31 |
$1,448 |
| 2013-09-30 |
$1,261 |
| 2013-06-30 |
$1,406 |
| 2013-03-31 |
$1,237 |
| 2012-12-31 |
$1,411 |
| 2012-09-30 |
$1,085 |
| 2012-06-30 |
$1,246 |
| 2012-03-31 |
$1,247 |
| 2011-12-31 |
$4,716 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
$1,178 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$312.695B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
